BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BEBT-109 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BEBT-109\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06514027-2100@assetmemo.bio
DTSTAMP:20261121T005842Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:BEBT-109: Phase 2 readout est. (NCT06514027)
DESCRIPTION:BEBT-109\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon
  20 Insertion Mutations\nEstimated primary completion: June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bebt-109#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06514027
URL:https://assetmemo.bio/drug/bebt-109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
